EUROGIN 2017 fostered multidisciplinarity and new scientific insights in HPV screening in Europe 
The EUROGIN 2017 Congress took place in Amsterdam this week. It aims at developing a full review of current scientific developments in the field of human papillomavirus related cancer and other diseases. The event endeavors to translate scientific discoveries into day-to-day clinical practice, including updated scientific insights in HPV screening, testing and management
Along those lines, Inge de Kok and Erik Janssen (both Erasmus MC) presented on “Challenges in quality assurance when adopting novel test systems: clinical validation and quality assurance of HPV tests in routine screening programmes” and “New evidence with regard to test characteristics from a modelling study”, respectively.
EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) brings together clinicians and scientists whose work is related to genital infections and neoplasia. As one of the most important conferences on human papillomavirus infection and related cancers, EUROGIN continues to foster multidisciplinary interactions that are vital to making critical discoveries.
The project was launched in September 2015 and will continue to August 2020.
This project has received funding from the European Unionʼs Horizon2020 Programme under grant agreement no 634753
